24
Participants
Start Date
June 6, 2018
Primary Completion Date
February 4, 2020
Study Completion Date
December 30, 2025
Avelumab
Avelumab (IV on days 1 and 15 of 28 day cycle)
Palbociclib
"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
Cetuximab
"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
UC San Diego Moores Cancer Center, La Jolla
Collaborators (1)
Pfizer
INDUSTRY
Kathryn Gold
OTHER